Rodon, J., Rothe, M., Garrett-Mayer, E., Rohatgi, N., Menendez, A. G., Elliott, L. A., … Schilsky, R. L. (2026). Abstract CT206: Larotrectinib (L) in patients (pts) with solid tumors with NTRK1/2/3 amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. In Cancer Research (Vol. 86, pp. CT206–CT206). American Association for Cancer Research (AACR). https://doi.org/10.1158/1538-7445.am2026-ct206

Rodon, Jordi, Michael Rothe, Elizabeth Garrett-Mayer, Nithin Rohatgi, Alvaro G. Menendez, Leighton A. Elliott, Andrew Gregory, et al. “Abstract CT206: Larotrectinib (L) in patients (pts) with solid tumors with NTRK1/2/3 amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.” In Cancer Research, 86:CT206–CT206. American Association for Cancer Research (AACR), 2026. https://doi.org/10.1158/1538-7445.am2026-ct206.

Rodon J, Rothe M, Garrett-Mayer E, Rohatgi N, Menendez AG, Elliott LA, et al. Abstract CT206: Larotrectinib (L) in patients (pts) with solid tumors with NTRK1/2/3 amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. In: Cancer Research. American Association for Cancer Research (AACR); 2026. p. CT206–CT206.

Rodon, Jordi, et al. “Abstract CT206: Larotrectinib (L) in patients (pts) with solid tumors with NTRK1/2/3 amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.” Cancer Research, vol. 86, no. 8_Supplement, American Association for Cancer Research (AACR), 2026, pp. CT206–CT206. Crossref, doi:10.1158/1538-7445.am2026-ct206.

Rodon J, Rothe M, Garrett-Mayer E, Rohatgi N, Menendez AG, Elliott LA, Gregory A, Hinshaw DC, Grantham GN, Halabi S, Schilsky RL. Abstract CT206: Larotrectinib (L) in patients (pts) with solid tumors with NTRK1/2/3 amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Cancer Research. American Association for Cancer Research (AACR); 2026. p. CT206–CT206.